K-80003
CAS No. 1292821-90-9
K-80003( —— )
Catalog No. M32977 CAS No. 1292821-90-9
K-80003(TX-803) is a potent retinol-like X-receptor-alpha regulator that inhibits TRxrα-dependent Akt activation and tumor cell growth.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 67 | In Stock |
|
| 2MG | 36 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 96 | In Stock |
|
| 25MG | 169 | In Stock |
|
| 50MG | 253 | In Stock |
|
| 100MG | 372 | In Stock |
|
| 200MG | 529 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameK-80003
-
NoteResearch use only, not for human use.
-
Brief DescriptionK-80003(TX-803) is a potent retinol-like X-receptor-alpha regulator that inhibits TRxrα-dependent Akt activation and tumor cell growth.
-
DescriptionK-80003 is a potent inhibitor of tRXRα-dependent Akt activation and cancer cell growth.
-
In VitroWhen MCF-7 cells are cotreated with K-80003, TNFα-induced colocalization of tRXRα with p85α in the cytoplasm is inhibited, resulting in tRXRα nuclear localization. Western blotting shows that K-80003-stabilized tetrameric form of tRXRα is found exclusively in the nuclear fraction, while tRXRα monomer is distributed both in the nuclear and cytoplasmic fractions.
-
In VivoK-80003 is a potent inhibitor of AKT activation by all-trans-retinoic acid. K-80003 displays enhanced efficacy in inhibiting tRXRα-dependent AKT activation and tRXRα tumor growth in animals. K-80003 has high affinity to RXRα but lacks COX inhibitory activity.
-
Synonyms——
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetAkt
-
RecptorRAR/RXR? | Akt
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1292821-90-9
-
Formula Weight336.4
-
Molecular FormulaC22H21FO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 30 mg/mL (89.18 mM; Ultrasonic )
-
SMILESCC(C)c1ccc(\C=C2\C(C)=C(CC(O)=O)c3cc(F)ccc23)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhou H, et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell. 2010 Jun 15;17(6):560-73.?
molnova catalog
related products
-
CCT128930
CCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2).
-
BI-69A11
A potent, selective, ATP competitive AKT inhibitor with IC50 of 2.3 uM for Akt1.
-
I-CBP112 hydrochlori...
I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors. I-CBP112 (1 mM) has little activity against other bromodomains.
Cart
sales@molnova.com